Company Description
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.
It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Country | Canada |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 16 |
CEO | William Williams |
Contact Details
Address: Bellevue Centre, Suite 300 West Vancouver, BC V7T 2X1 Canada | |
Phone | 604-921-1810 |
Website | briacell.com |
Stock Details
Ticker Symbol | BCTX |
Exchange | NASDAQ |
Fiscal Year | August - July |
Reporting Currency | USD |
CIK Code | 0001610820 |
CUSIP Number | 10778Y302 |
ISIN Number | CA1079301091 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. William V. Williams M.D. | Chief Executive Officer, President and Director |
Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 1, 2024 | 8-K | Current Report |
Oct 29, 2024 | 10-K | Annual Report |
Oct 2, 2024 | 8-K | Current Report |
Oct 2, 2024 | 424B5 | Filing |
Oct 1, 2024 | 8-K | Current Report |
Sep 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Sep 12, 2024 | 8-K | Current Report |
Sep 12, 2024 | 424B5 | Filing |
Sep 11, 2024 | 8-K | Current Report |